Cardiovascular medicines : comparative costs and benefits

Abstract

A poster presentation regarding Cardiovascular medicines: comparative costs and benefits. Introduction: An increase in global life expectancy and a concomitant shift in population demographics is leading to a greater incidence of non-communicable disease, with cardiovascular(CVA) morbidity being the primary cause of death worldwide. In 2010, 17.3 million deaths and €863 million in healthcare interventions were attributed to CVA disease at a global level. With the same trends exhibiting themselves locally, consideration of the cost of treatment and financial factors was a topical issue. Aims: • Obtain the costs of all cardiovascular drugs found in the local private retail community setting • Analyse the prices of generic and proprietary products and derive a relationship • Observe the effect of a price differential for equivalent products to their sales volume over time.